In CH-C patients with IL28B C/C genotype, 65% (15/23) achieved SVR as compared to 24% (8/33) in CH-C patients with IL28B T* genotype (p < 0.05). This evidence concerns the gene IFNL3 and cyclic hematopoiesis.